last authored: Amy Nason, MD 2010, Dalhousie University, June 2009
last reviewed:
Also known as mucocutaneous lymph node disease, Kawasaki disease (KD)is a condition affecting children that causes inflammation, primarily of the arteries throughout the body, but also of the lymph nodes, skin and mucous membranes.
findings associated with KD, courtesy of Dong Soo Kim
It typically affects children between the ages of 2 and 5 years, with boys being affected more often than girls and those of Asian descent having slightly higher risk. It is very rare in infants younger than 3 months of age.
a simple case introducing clincial presentation and calling for a differential diagnosis to get students thinking.
Also known as mucocutaneous lymph node disease, Kawasaki disease is a condition affecting children that causes inflammation, primarily of the arteries throughout the body, but also of the lymph nodes, skin and mucous membranes.
It typically affects children between the ages of 2 and 5 years, with boys being affected more often than girls and those of Asian descent having slightly higher risk. It is very rare in infants younger than 3 months of age.
Inflammation leads to necrosis of smooth muscle and ultimately the intima proliferates and thickens.
Phase One
Phase Two
Phase Three
Clinical suspicion of Kawasaki disease is high when a child has a fever lasting at least 4 days and 4 or more of the following:
CBC: usually elevated white count, occasionally normocytic anemia and potentially thrombocytosis (rarely leading to thrombocytopenia)
Acute phase reactants: often elevated ESR and CRP
Liver enzymes: transaminases are elevated in approximately half of confirmed cases, a small percentage of children get an elevated bilirubin level
Urinalysis: pyuria and proteinuria may develop
Cardiac enzymes: elevated if infarction results as a consequence of inflammatory damage
EKG: used to detect myocarditis or infarction
Other diseases that must be ruled out with a presentation suggestive of Kawasaki disease are:
Typically these patients are managed by a rheumatologist. The main goals of treatment are to prevent coronary artery disease and relieve symptoms. The mainstays of treatment are:
intravenous gamma globulin (IVIG at 2g/kg)
anti-inflammatory medications (ie. Aspirin 80-100mg/kg/day in TID or QID divided doses during time of fever followed by 3-5 mg/kg/day OD once fever subsided)
Patients are kept in hospital until the fever subsides, after that the risk of developing significant heart disease is greatly lowered. They should be re-evaluated one week post-discharge and then have a repeat echocardiogram at one month. Generally treatment with aspirin is continued for up to six months but duration is greatly affected by clinical presentation and likelihood of long-term complications.
KD is the leading cause of acquired heart disease in children in North America. During the course of the illness about 20% (1 in 5) children will develop some form of heart problem but only a minority having lasting damage. The various heart problems are:
authors:
reviewers: